---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027132"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2026-06-03T21:22:06+00:00"
generated_at: "2026-06-03T21:24:26.129698+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Celularity names Rick Gonzalez Chief Commercial Officer, advances longevity and cenplacel-L focus

## Summary
- Rick Gonzalez appointed CCO effective May 29, 2026, reporting to Chairman & CEO Robert Hariri.
- Gonzalez has 20+ years biotech experience; previously CCO at Alume Biosciences, CEO at Navidea.
- Company sharpens focus on longevity, regenerative medicine; cenplacel-L sees physician demand in Florida.
- Out-licensed biomaterials to NexGel for up to $30M, reducing liabilities by ~$13M (previously announced).

## SEC filing metadata
- accession: 0001493152-26-027132
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2026-06-03T21:22:06+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/0001493152-26-027132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027132
- JSON: https://secwatch.observer/filing/0001493152-26-027132.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027132.txt

## Key facts
- Executive change
  Rick Gonzalez was appointed as Chief Commercial Officer at Celularity Inc.
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/0001493152-26-027132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.